Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The pivotal Harmoni-GI3 study has started enrolling patients.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
The project has priority review, but deaths could raise eyebrows.
An in vivo Car-T produced a 100% response rate – in three patients.
